Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: Report from the International Club of Ascites

Liver International

Volumn 33, Issue 1, 2013, Pages 16-23

  Angeli, Paolo ^a   Sanyal, Arun ^b   Moller, Soren ^c   Alessandria, Carlo ^d   Gadano, Adrian ^e   Kim, Ray ^f   Sarin, Shiv K ^g   Bernardi, Mauro ^h  

^a UNIVERSITY OF PADOVA   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF TURIN   (Italy)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f MAYO CLINIC   (United States)

^g INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Albumin; Hepatorenal syndrome; Renal failure; Serum creatinine; Terlipressin

Indexed keywords

ALBUMIN; CREATININE; LIPOPOLYSACCHARIDE; TERLIPRESSIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; BACTERIAL INFECTION; BACTERIAL TRANSLOCATION; CARDIOMYOPATHY; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DIFFERENTIAL DIAGNOSIS; END STAGE LIVER DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTOXEMIA; GLOMERULONEPHRITIS; HEMODYNAMICS; HEPATORENAL SYNDROME; HOSPITAL PATIENT; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER SUPPORT; LIVER TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MORTALITY; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT; PHENOTYPE; PREDICTION; PROSPECTIVE STUDY; REVIEW; SEPTIC SHOCK; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; URINALYSIS; URINARY EXCRETION; URINE VOLUME;

DIAGNOSIS, DIFFERENTIAL; HEPATORENAL SYNDROME; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; MULTIPLE ORGAN FAILURE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84870851072     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02807.x     Document Type: Review

References (67)

1. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22: 5-13.
2. Gines P, Schier RW. Renal failure in cirrhosis. New Engl J Med 2009; 361: 1279-90.
3. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 105-10.
4. Llach J, Ginès P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
5. Lim YS, Larson TS, Benson JT, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol 2010; 52: 523-8.
6. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 8: 2064-77.
7. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.
8. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria a of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
9. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut 2007; 56: 1310-8.
10. Cruz DN, Bagshaw SM, Ronco C, Ricci Z. Acute kidney injury: classification and staging. Contrib Nephrol 2010; 164: 24-32.
11. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008; 73: 538-46.
12. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
13. Jenq CC, Tsai MH, Tian YC, et al. RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intensive Care Med 2007; 33: 1921-30.
14. Cholongitas E, Calvaruso V, Senzolo M, et al. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol 2009; 24: 1639-47.
15. Tu KH, Jenq CC, Tsai MH, et al. Outcome scoring systems for short-term prognosis in critically Ill cirrhotic patients. Shock 2011; 36: 445-50.
16. Fagundes C, Guevara M, Garcia-Lopez E, et al. Comparison of Akin criteria and conventional criteria for definition of renal impairment in cirrhosis: preliminary results of a prospective study. J Hepatol. 2010; 52(Suppl. 1): S329. (Abstract).
17. Fagundes C, Guevara M, Garcia-Lopez E, et al. Acute kidney injury network (AKIN) criteria for acute renal failure predicts outcome in hospitalized cirrhotic patients: a prospective study. J Hepatol 2011; 54(Suppl. 1): 541 (Abstract).
18. Wong F, Nadim MK, Kellum JA, et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702e709.
19. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154: 201-5.
20. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41: 269e78.
21. Freeman RB, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-8.
22. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011; 54: 1297-306.
23. Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008; 300: 2371-8.
24. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re-weighting the model for end-stage liver disease score components. Liver Transpl 2009; 15: 1808-13.
25. Francoz C, Prié D, Abdelrazek W, et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010; 16: 1169-77.
26. Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10: 301-9.
27. MacAulay J, Thompson K, Kiberd BA, et al. Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better? Can J Gastroenterol 2006; 20: 521-6.
28. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605-13.
29. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-10.
30. Umgelter A, Wagner K, Reindl W, et al. Haemodynamic effects of plasma-expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study. BMC Gastroenterol 2008; 8: 39.
31. Trawalé JM, Paradis V, Rautou PE, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 2010; 30: 725-32.
32. Cavallin M, Fasolato S, Sticca A, et al. Increased urinary level of neutrophil gelatinase-associated lipocalin (NGAL) in patients with cirrhosis and type 1 HRS. Hepatology 2011, 54(Suppl. 4): 1254A-5A (Abstract).
33. Singer E, Elger A, Elitok S, et al. Luft FC, Schmidt-Ott KM Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. Kidney Int 2011; 80: 405-14.
34. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
35. González M, Navasa M, Monescillo A, et al. Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8.
36. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-47.
37. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-90.
38. Navasa M, Follo A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227-32.
39. Francés R, Zapater P, González-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47: 978-85.
40. Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52: 2044-52.
41. Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 2010; 53: 298-306.
42. Wang W, Jittikanont S, Falk SA, et al. Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol Renal Physiol 2003; 284: F532-7.
43. Knotek M, Rogachev B, Wang W, et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001; 59: 2243-9.
44. Sanyal A, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double blind placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
45. Martin-Llahi MM, Pepin MN, Guevara M, et al. Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.
46. Gluud LL, Christensen K, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-84.
47. Angeli P. Review article: prognosis of hepatorenal syndrome: has it changed with current practice? Aliment Pharmacol Ther 2004; 20(Suppl. 3): 44-6.
48. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. The Terlipressin Study Group. Impact of liver transplantation on survival of patients treated for type 1 hepatorenal syndrome (HRS-1). Liver Transpl 2011; 17: 1328-32.
49. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on post-transplantation outcome. A case control study. Liver Transpl 2004; 40: 140-6.
50. Narahara Y, Kanazawa H, Taki Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009; 24: 1791-7.
51. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Møller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004; 39: 486-92.
52. Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 1085-92.
53. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
54. Ceolotto G, Paparella I, Cavallin M, et al. First evidence that albumin can directly improve cardiac contractility in cirrhotic rats. Hepatology 2007; 46: 865A-6A (Abstract).
55. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Tsianos EV. Bacterial translocation attenuates the systemic hemodynamic improvement produced by terlipressin in patients with cirrhosis. Hepatology 2011; 54: 743-4.
56. Moreau R, Barrière E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology 2002; 36: 1070-8.
57. Fernandez J, Navasa M, Garcia-Pagan JC, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004; 41: 384-90.
58. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011; 55: 315-21.
59. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 HRS. Hepatology 2010; 51: 219-26.
60. Ginès P, Angeli P, Lenz K, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 347-417.
61. Velez JCQ, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal sundrome parallels increase in mean arterial pressure: a polled analysis of clinical trials. Am J Kidney Dis 2011; 58: 928-38.
62. Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997; 26: 621-7.
63. Morelli A, Ertmer C, Lange M, Westphal M. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better? Intensive Care Med 2007; 33: 1669-70.
64. Gerbes AL, Huber E, Gülberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179.
65. Angeli P, Fasolato S, Cavallin M, et al. Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study. Hepatology 2008; 48: 378A (Abstract).
66. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64.
67. Rifai K, Kribben A, Gerken G, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (HELIOS Study): a prospective randomized controlled multicenter study. J Hepatol 2010; 52: S3 (Abstract).